Picture of 180 Life Sciences logo

ATNF 180 Life Sciences Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-25.93%
3m-28.54%
6m-78.83%
1yr-94.24%
Volume Change (%)
10d/3m+210.1%
Price vs... (%)
52w High-94.6%
50d MA-26.24%
200d MA-71.97%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-29632.07%
Return on Equity-312.04%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of 180 Life Sciences EPS forecast chart

Profile Summary

180 Life Sciences Corp. is a clinical-stage biotechnology company. The Company is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing research, and combination therapy. The Company's focus is a program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms Anti-TNF platform, SCAs platform and a7nAChR platform. The Anti-TNF platform is focused on the fibrosis and anti-tumor necrosis factor (anti-TNF). The SCAs platform is focused on the drugs that are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). The a7nAChR platform, which is focused on the alpha 7 nicotinic acetylcholine receptor (a7nAChR). It is conducting clinical trials only for certain indications under the anti-TNF platform. The Company is also undertaking preclinical research and development activities for the SCA and the a7nAChR platforms.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
September 7th, 2016
Public Since
June 7th, 2017
No. of Shareholders
123
No. of Employees
5
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
852,758

ATNF Share Price Performance

Upcoming Events for ATNF

Q4 2023 180 Life Sciences Corp Earnings Release

Q1 2024 180 Life Sciences Corp Earnings Release

180 Life Sciences Corp Annual Shareholders Meeting

Q2 2024 180 Life Sciences Corp Earnings Release

Similar to ATNF

Picture of Abeona Therapeutics logo

Abeona Therapeutics

us flag iconNASDAQ Capital Market

Picture of ABVC Biopharma logo

ABVC Biopharma

us flag iconNASDAQ Capital Market

Picture of Acesis Holdings logo

Acesis Holdings

us flag iconNASDAQ Capital Market

Picture of Achieve Life Sciences logo

Achieve Life Sciences

us flag iconNASDAQ Capital Market

Picture of Aclarion logo

Aclarion

us flag iconNASDAQ Capital Market

FAQ